MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00427102
Recruitment Status : Terminated (No subjects enrolled and PI went to another facility)
First Posted : January 26, 2007
Last Update Posted : November 14, 2012
Information provided by:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:

Rationale for Study

Oral mucositis is a major complication arising from contemporary chemoradiation treatment of patients with head and neck cancer.

No effective therapy exists to prevent this complication in this population. MRX-1024 is an investigational agent that has demonstrated in in vitro and in vivo experiments to have the potential to exert a protective effect in normal mucosa cells, without interfering with the intended antitumor effect of radiation.

A pilot Phase 1 study of MRX-1024 was conducted in India in patients with head and neck cancer receiving radiation alone or radiation in combination with cisplatin or carboplatin. MRX 1024 doses of 100 mgkg given orally twice a day, five days a week during radiation treatment cycles, were well tolerated and appeared to exert a protective effect against the development of severe mucositis.

Twice daily doses of MRX 1024 impose a certain level of inconvenience to the patient, to their clinic companion, and to the general work flow within radiation oncology clinics.

This study is designed to study the safety and pharmacokinetics of both single daily dose and twice daily dose regimens of oral MRX 1024 given in conjunction with daily radiation fractions and intermittent high-dose cisplatin to patients with high-risk for recurrence head and neck cancer following surgical resection. The study will also document the incidence and severity of oral mucositis that occurs following such therapy. The results will be instrumental in determining the regimen of MRX 1024 to use in subsequent definitive clinical trials.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma Head and Neck Cancer Resected Head and Neck Cancer Mucositis Drug: Oral MRX-1024 Procedure: Standard Fractionation Radiation Therapy Drug: High-Dose Cisplatin Chemotherapy Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection
Study Start Date : January 2007
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Primary Outcome Measures :
  1. safe recommended doses and dose regimen for oral MRX-1024 with concurrent chemoradiation.
  2. Identify toxicity profile of oral MRX-1024.
  3. Determine pharmacokinetic parameters of oral MRX-1024.

Secondary Outcome Measures :
  1. Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy-proved squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx;
  • Status-post surgical resection of primary disease and meeting criteria for post-operative radiotherapy and chemotherapy by evidence of histologic extracapsular nodal extension, or histologic involvement of >2 regional lymph nodes, or mucosal margin of resection with invasive cancer (limited to microscopic detection only);
  • Able to begin protocol treatment within 8 weeks of first tumor-related surgery;
  • Age >18 years. Because no dosing or adverse event data are currently available on the use of MRX-1024 in combination with radiotherapy and cisplatin or carboplatin, in patients less than 18 years of age, children are excluded from this study, but will be eligible for future pediatric Phase 1 combination studies in appropriate indications when sufficient safety and efficacy data in adults are available.
  • Karnofsky Performance Status of >70 (Appendix I);
  • Normal organ and marrow function as defined herein, determined by laboratory values obtained within seven days prior to receiving the first dose of protocol treatment:

    • Serum creatinine within institutional limits of normal
    • Creatinine clearance >50
    • Total bilirubin within institutional limits of normal
    • AST(SGOT) and ALT(SGPT) <2.5 times the upper limit of normal for the institution
    • White blood cell count >3500 per cubic millimeter
    • Absolute neutrophil count >1500 per cubic millimeter
    • Platelet count >100,000 per cubic millimeter
  • Ability to understand and the willingness to sign an informed consent document in accordance with institutional guidelines.

Exclusion Criteria:

  • Gross (visible or palpable) disease left after surgical resection;
  • Prior chemotherapy or radiation therapy to the head and neck region;
  • Primary site of the lip, nasopharynx or paranasal sinuses;
  • Distant metastases;
  • Known malabsorption syndrome;
  • Pregnancy or breast-feeding. The effects of MRX-1024 on the developing human fetus are unknown at this time. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) for the duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately;
  • Gastrointestinal tract disease or deformity resulting in an inability to take oral or enteral medication or nutrition;
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, untreated or new cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements;
  • History of taking any investigational medication within 4 weeks prior to receiving the first dose of protocol treatment.
  • Prior malignancy within the previous 5 years, excluding non-melanoma skin cancer and cervical cancer treated with local therapy.
  • Known allergy or sensitivity to polysorbate 80 (Tween).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00427102

Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator: Gopal Bajaj, M.D. Johns Hopkins University Identifier: NCT00427102     History of Changes
Other Study ID Numbers: J-0657
First Posted: January 26, 2007    Key Record Dates
Last Update Posted: November 14, 2012
Last Verified: November 2012

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
Oral MRX-1024
High-Dose Cisplatin Chemotherapy
Standard Radiation Therapy

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Antineoplastic Agents